bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P1-09-08: Breast cancer (BC) outcomes after implementation of “Seguro popular” at the National Institute of Medical Sciences and Nutrition, Salvador Zubiran (INCMNSZ) in Mexico
Authors: Castro Sánchez A , Meneses Medina MI , Chávarri Guerra Y , Pérez Álvarez SI , León Rodríguez E , Armengol Alonso A 
Published: August 2014

Abstract
Background: In Mexico 60% of newly diagnosed BC patients present with locally advanced disease. In the United States, 88-95% of patients present with early stage disease, however in Mexico, only 10% of patients are diagnosed at this stage. The Seguro Popular (SP), a national insurance scheme for Mexico's poor and uninsured population, was implemented for BC in 2007. The SP covers diagnostics, local and systemic treatment for BC patients. The INCMNSZ is a third level hospital where patients receive diagnosis and treatment for non-malignant diseases, and also routinely conducts BC annual mammography screening for women ≥ 50 years old. We aimed to evaluate BC outcomes in our patients following the implementation of SP at our institution.
Methods: From January 2011 to May 2013, we prospectively evaluated a cohort of 93 patients with BC included in the SP program at the INCMNSZ. A retrospective cohort of 99 patients without SP access who received neoadjuvant chemotherapy from January 2007 to December 2009 was used for comparative analysis. Complete pathologic response (pCR) was defined as complete absence of invasive tumor in breast and axillary nodes. We used Fisher's exact test to compare pCR between groups.
Results: A total of 93 patients were diagnosed with BC and included in the SP program. 10 patients were excluded from the analysis- (5 were lost to follow-up and 5 had missing data. Median age was 52 (46-59) years and 37 patients (45%) were premenopausal at diagnosis), median follow up 11.8 months. 20 patients (24%) had stage I, 36 (43%) stage II, 7 (8%) stage III, and 20 (24%) stage IV. 55 (66%) patients had hormone receptor (HR) positive (ER + and/or PR+), 15 (18%) HER2+ and 13 (16%) had triple negative (TN) tumors. Thirty-two (39%) patients received neoadjuvant chemotherapy. 27% of patients achieved pCR (17% in HR positive, 20% in TN and 50% in HER2+ tumors) compared to 15% in the non SP cohort (11% in HR positive, 22% in TN and 14% in HER2+ tumors). HER2+ tumors from the SP cohort reached significantly higher pCR rates than in the non SP cohort (p = 0.029).
Discussion: Our results confirmed that about half of our patients were diagnosed with early stage BC, which highlights the importance of a screening program at our institution. Increased pCRs in the HER2+ subgroup may reflect wider access to trastuzumab after implementation of SP. Although we acknowledge a short period of follow-up in our cohort, our results in pCR are comparable to those previously reported in the literature. We believe the SP had a positive impact on access to care and outcomes in our patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-09-08.
Abstract P1-09-11: Can patient navigation help overcome barriers to breast cancer treatment in patients with health care disparities?
Authors: Elrafei T , Castaldi M , Shaker A , Stanise T , Gralla R , Matquez M , Bodner W , Reed L , Strakhan M , Alexis K 
Published: August 2014

Abstract
Background: Patient navigation has been demonstrated to aid in adherence to breast cancer screening initiatives. Fewer studies have documented benefit for patients undergoing treatment, and especially among those with barriers to care. Cancer health disparities affecting low-income and minority patients are well documented. Causes of poor outcomes include treatment delays coupled with social and financial barriers. This report examines the impact of patient navigation on adherence to prescribed cancer treatment, including in patients receiving treatment in adjuvant and metastatic breast cancer settings.
Methods: This Patient Navigation project (supported by an Avon Foundation grant) was initiated at our public safety net hospital to test whether there was sufficient benefit to warrant a larger randomized trial. Health care coverage included 58% Medicaid, 7% uninsured or undocumented. This study was conducted over a 4 month period with new medical oncology practice patients. Those deemed to be at high risk for non-adherence received navigated care. Navigator duties included care coordination, appointment reminders, patient education materials, translation services, and transportation arrangement. Data collected prospectively included patient characteristics, cancer type, time from referral to first RT, and compliance with visits; this was compared with usual care controls during the 4 month period.
Results: Patient Navigation Program patient characteristics: N = 52 patients (42% breast cancer, 12% prostate cancer, 10% lung cancer and 36% with other cancers). Mean age = 55; 48% Black, 38% Hispanic, 8% Asian, 6% White. The table below gives the results of percentage of adherence to visits (and time to first RT) for all patients in the study receiving navigated care, for just the patients with breast cancer receiving navigated care, and for the usual care control (no navigated care).
Table 1. NAVIGATED CARE: ALL PATIENTS (N = 52)NAVIGATED CARE: BREAST CANCER (n = 22)USUAL CARE GROUPPhysician Visits (Medical Oncology)(141 Visits) 90% (95% CI: 84%-95%)(56 Visits) 91% (95% CI: 80%-97%)(2021 Visits) 79% (95% CI: 77%-81%)Chemotherapy Treatment(107 Treatments) 95% (95% CI: 89%-99%)(30 Treatments) 97% (95% CI: 83%-99%)(1656 Treatments) 86% (95% CI: 84%-88%)Time to first RT32 Days (n = 25)35 Days (n = 8)30 Days
Conclusions: This Patient Navigation Program is associated with observed improvements in adherence to chemotherapy and in follow up physician visits. No impact on time to first RT was shown. These results document that a Patient Navigation Program can help overcome barriers to good cancer care.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-09-11.
Abstract P1-09-12: The interplay of biologic factors, race, and delivery of care in improving breast cancer outcomes
Authors: Weber JJ , Kachare SD , Vohra NA , Fitzgerald TF , Wong JH 
Published: August 2014

Abstract
Importance: A marked disparity exists in the breast cancer mortality of women diagnosed in Eastern North Carolina (ENC) when compared to women diagnosed in the rest of North Carolina (RNC).
Objective: To identify modifiable factors associated with the increased mortality of women diagnosed with breast cancer in ENC.
Design: Retrospective cohort study of women diagnosed with breast cancer in North Carolina between January 1, 2004 and December 31, 2007.
Setting: North Carolina Central Cancer Registry.
Participants: Females diagnosed with either invasive or non-invasive breast cancer in North Carolina during the designated time period.
Main Outcome Measures: Race/ethnicity, hormone receptor status, pathologic T, N and stage grouping at the time of diagnosis, delivery of adjuvant chemotherapy, and survival.
Results: A total of 27,631 women were diagnosed with breast cancer during the study period. Women in ENC were slightly older than in RNC (59.2 y v. 58.5 y, p&lt;0.001). There was no difference in the pathologic T (p = 0.62), N (p = 0.26) or Stage Grouping (p = 0.25) at diagnosis between ENC and RNC patients. Women in ENC were less likely to be White (68.9% v. 80.0%, &lt;0.001)), ER positive (53.4% v. 59.4%, p&lt;0.001), PR positive (44.8% v. 49.4%, p&lt;0.001), or to receive adjuvant chemotherapy (78.7% v. 81.3%, p = 0.02). The median survival of ENC patients was significantly worse than RNC patients (39 months v. 43 months, p = 0.003). By univariate analysis, improved median survival was associated with ER status (p&lt;0.001), PR status (p&lt;0.001), Race/ethnicity (p&lt;0.001) and delivery of timely chemotherapy (p&lt;0.0001). By Cox Regression analysis, ER negative status (RR 1.03; 95% CI 0.85 to 0.98, p = 0.01), African American (RR 0.94; 95% CI 0.89 to 0.99, p = 0.03), and adjuvant chemotherapy within 90 days of surgery (RR 1.40; 95% CI 1.30 to 1.50, p&lt;0.001) remained significant predictors of survival.
Conclusions: The poor outcomes observed in ENC can be attributed to recognized prognostic primary patient and tumor characteristics. However a failure in process of care remains significantly associated with poorer outcomes. Improved timing of delivery of chemotherapy could affect breast cancer mortality.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-09-12.
Abstract P1-13-01: Risk of recurrence following 5 years of adjuvant hormone therapy for hormone receptor positive early breast cancer.
Authors: Lohrisch C , Speers C , Chia S , Kennecke H , Ellard S , Tyldesley S 
Published: August 2014

Abstract
Background
Introduction
The MA.17 study and combined analysis of the ATLAS and aTTom studies provide evidence of DFS and modest OS benefit from 10 years of hormone therapy (HT) for hormone receptor positive early breast cancer. The benefit may be less for women diagnosed today, due to advances in chemotherapy, initial HT, and radiation therapy since the era when these trials were conducted. Side effects accrue to all users of longer HT while benefit is experienced only by those who avoid recurrence, which is related to the baseline prognostic factors such as stage, grade, and disease biology.
Methods
To enhance informed patient-physician discussions, starting with a cohort of 10815 stage I-III hormone receptor breast cancer diagnoses between 1989 and 2004, we examined event-free survival (EFS) in years 5 to 10 among 1,061 premenopausal (&lt;45 years at diagnosis) and 6,615 menopausal (≥50 years at diagnosis) women without documented relapse, CLBC, or death within the first 5 years. All patients were referred to the BC Cancer Agency (BCCA) with newly diagnosed disease, and all patients had adjuvant HT. EFS was defined as freedom from recurrence, from CLBC, or from breast cancer death without prior documented recurrence.
Results
Median follow up for the 7676 patients is 11 years. Event rates (including CLBC) in the second 5 years from diagnosis for stage I, II and III cancers were 6%, 12%, 23% for the pre-menopausal cohort, and 5%, 14%, 26% for the post-menopausal cohort. EFS in years 5-10 varied significantly by grade as shown below:
EFS years 5-10 after ER+ early Breast CancerStage, gradeAge 45 and younger at diagnosisAge 50 and older at diagnosis NEvents% EFS years 5-10 (95% CI)NEvents% EFS years 5-10 (95% CI)I, grade 1110698.2 (92.9,99.5)10375795.4 (93.7,96.6)I, grade 21741692.1 (86.7,95.3)133811194.6 (93.1,95.7)I, grade 368593.4 (83.2,97.5)3642994.8 (91.8,96.8)II, grade 174889.6 (78.0,95.3)6056193.0 (90.5,94.9)II, grade 22905186.3 (81.6,89.9)177330786.6 (84.8,88.2)II, grade 32103090.4 (85.4,93.8)82318781.9 (78.9,84.5)III, grade 160100531175.6 (59.6,86.0)III, grade 2591574.3 (60.6,84.1)2526774.3 (67.8,79.8)III, grade 3521178.0 (62.1, 87.9)1504072.0 (62.8,79.3)CI, confidence Intervals
Recurrences (excluding CLBC) after 10 years was 2% for the 10815 cases (representing 12% of all recurrences).
Conclusion
These data suggest that pre and postmenopausal women with stage I cancers of any grade, and postmenopausal women with stage II grade 1 cancers who have not experienced a relapse in the first five years can expect a less than 10% risk of recurrence, breast cancer death, or CLBC without further HT over the next 5 years. Prolonged HT in the identified groups may result in higher probability of harm than benefit and may best be avoided, although long term data will be needed to fully inform this risk benefit analysis.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-13-01.
Abstract P1-13-15: Risk of late recurrence of hormone receptor positive breast cancer in cases with no recurrent disease at five years after surgery
Authors: Ohno S , Koui Y , Oikawa M , Akiyoshi S , Koga C , Igawa A , Saruwatari A , Nishimura S , Nakamura Y , Taguchi K , Ishida M 
Published: August 2014

Abstract
Background: Among women who take 2-5 years of adjuvant endocrine therapy, more than half of all recurrences of hormone receptor (HR) positive breast cancer occur after the first 5 years. Data from large clinical trials including ATLAS, aTTom,MA17 and NSABP B-30 support extending tamoxifen or aromatase inhibitor beyond 5 year for women with HR positive breast cancer. For decision making according to extending endocrine therapy, the information of the risk of late recurrence is quietly important.
Patients and methods: In order to determine ten year disease free survival (DFS) rates, we reviewed medical records and database of patients who were treated at National Kyushu Cancer Center between 1990 and 2001. Among seven hundred fifty seven patients with HR positive breast cancer, 550 received tamoxifen for 2-5 years. Eighty eight patients had recurrence within five years after surgery, and 13 were not followed, with 83.5% of 5-year DFS after surgery. Remaining four hundred twenty six had no recurrence at the time of 5 years after surgery. To evaluate the risk of late recurrence, we analyzed the long-term results in association with clinicopathological factors for these 426 patients.
Results: Four hundred twenty six patients had 87.1% of 10-year DFS rate. According to lymph node metastasis (N), ten year DFS rates were 91.4% for 275 N-negative and 80.0% for 155 N-positive cases (P = 0.0037). As for the number of lymph node metastasis, 10-year DFS rates were 82.5%, 74.2%, and 79.1% for N1-3, N4-9, N&gt;9, respectively. Tumor size was correlated with the prognosis, and 10-year DFS rates were 91.5% for 167 T1 (≤2 cm), 86.9% for T2 (2-5 cm), and 67.9% for T3 (&gt;5cm) (P = 0.0334). There were no significant differences between grade and prognosis, and 10-year DFS rates of grade 1, 2 and 3 were 88.9%, 89.8%, and 96.8%, respectively (p = 0.3914). Considering the age at 5 years after surgery, no significant differences were observed as for late recurrence. Ten-year DFS rates of 96 cases of age under 50, 227 between 50 and 65, 113 over 65 was 89.4%, 85.1%, and 86.0%, respectively. Ten-year DFS rates of N-negative and N-positive were 94.3% and 81.2%, 88.1% and 80.1%, and 90.4% and 76.7% for these age criteria, respectively.
Conclusion: Patients with HR positive breast cancer require optimal information for decision making whether to receive extending endocrine therapy or not. Our data demonstrated the risk of late recurrence in relation to clinic-pathological factors, which may support the consideration about extending endocrine therapy. Relatively high risks of late recurrence with over 10% of 10 year DFS rates are there in cases with N-positive or T2-3 HR positive breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-13-15.
Abstract P2-02-01: Did established clinical practice regarding MRI bias the COMICE trial?
Authors: McMahon MA , Sharma N , Shaaban A , Dall BJG 
Published: August 2014

Abstract
Introduction: The negative COMICE study and reports of inappropriate mastectomies worldwide have served to discredit the use of preoperative MRI for the purpose of aiding conservative breast surgery. We postulate that established clinical practice regarding MRI at the time of the COMICE trial lead to bias in case selection, with more complicated cases being preselected out prior to randomisation. We reviewed the local practice at the time of COMICE.
Methods and materials: Retrospective analysis of all cases of Breast MRI performed to assess disease extent pre-operatively during recruitment to COMICE (December 2001 - January 2007) was undertaken. Size on mammogram/ultrasound, MRI and histology was documented. As pre-PAC's era, the information was obtained from imaging and pathology reports. Where reports did not include distance between lesions in multifocal/multicentric disease, the sum of the lesions was used (taken as immediately adjacent) so as not to overestimate the size. All cases were reviewed blinded to COMICE status. Cases with mammogram/ultrasound size &gt;/ = 40mm were excluded as these were deemed unsuitable for conservative surgery.
Results: A total of 318 breast MRI examinations were performed in this interval to assess disease extent pre-operatively of which, 81 were excluded appropriately, for inadequate information (n = 47), size on conventional imaging &gt;/ = 40mm (n = 18), receiving neo-adjuvant treatment (n = 6), non cancer diagnosis (n = 7) and non invasive disease (n = 3). 242 cancers from 237 patients were included comprising 77COMICE and 160NON-COMICE patients. Statistical difference was noted in the types of surgery between the groups, p&lt;0.001. Re-excision rates were similar: COMICE = 11.7% and NON-COMICE = 8%. Mastectomy rates were however different, 15.6% of the COMICE group and 42% of the NON-COMICE group.
There was a significant difference in histological size between the 2 groups, mean size in NON-COMICE cases 32mm versus 26mm in the COMICE group (p = 0.009). There was a significant difference in the tumour types between the 2 groups (p&lt;0.001). Notably 37% of cases in the NON-COMICE group were of lobular type compared to 13% of the COMICE group.
Conclusion: Data from this well established MRI unit has demonstrated clinical bias in the COMICE trial with more complicated cases, which benefited from MRI, being pre-selected out prior to randomisation which understated the value of MRI. MRI in appropriately selected patients in conjunction with modern oncoplastic surgical techniques will increase the opportunities for conservative surgery rather than increase mastectomy rates. An aggressive biopsy policy for MRI detected lesions is required to avoid inappropriate mastectomies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-02-01.
Abstract P2-02-08: MRI in predicting pathological response of breast cancer after neoadjuvant chemotherapy: Correlation with tumor size and morphology changes
Authors: Woo O , Seo JH , Yang DS , Kim WY 
Published: August 2014

Abstract
PURPOSE
Contrast enhanced MR imaging is widely used to monitor the response of neoadjuvant chemotherapy (NAC) in breast cancer patients. The objectives of the study are 1) to assess the response of neoadjuvant chemotherapy (NAC) according to molecular biomarker status using MRI, 2) to evaluation of changes in morphological variation, and 3) to compare MR imaging-pathological size discrepancy depending on molecular biomarker status.
MATERIALS AND METHODS
Between May 2007 and March 2012, a total of 47 patients (age range, 34-65 years; mean age, 48 years) underwent NAC prior to surgery. Among them, 34 patients who performed MRI before and after NAC were enrolled. The extent of the lesion is measured by longest diameter. The response to NAC was calculated as reduction rate between pre NAC MRI and post NAC MRI. Histological grading system - Miller and Payne grade - was also recorded. Patients were divided into subgroups based on human epidermal growth factor receptor 2 (HER2), hormone receptors (HRs), and the proliferation marker Ki-67 status. The morphologic changes were classified into 1) concentric reduction, 2) fragmentation, 3) non-mass like, and 4) architectural distortion.
RESULTS
Total of 34 lesions from 34 patients were included. Among them, 12 lesions (35.3%) were pathologically proven to have no residual tumor (Miller and Payne grade 5). The mean MR reduction rate tended to be higher in HER2-positive (62.7%) and triple negative subgroups (61.9%) than HR-positive subgroup (47.7%). The mean MR imaging-pathologic size discrepancy tended to be smaller in triple negative subgroup (0.5cm) than HER2-positive (1.2cm) and HR-positive subgroups (1.4cm). All results showed no statistical significance (P&gt;0.05). Ki-67 expression showed no significant correlations in tumor response (r = 0.17, P = 0.4) and MR imaging-pathologic size discrepancy (r = 0.1, P = 0.6). The majority of morphologic change is concentric reduction (57.6%). MRI is tended to overestimate residual size of the lesion (62.5%)
CONCLUSION
HER2-positive and triple negative subgroups showed relatively better response. Tumors were most likely to response in the manner of concentric reduction. The mean MR imaging-pathologic size discrepancy tended to be smaller in triple negative subgroup. MRI is reliable method in predicting histopathological response to NAC, but is more likely to overestimate the residual size of the lesion.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-02-08.
Abstract P2-04-05: Pros and cons of breast cancer screening: Knowledge in lay women
Authors: Morère J-F , Pivot X , Touboul C , Viguier J , Blay J-Y , Coscas Y , Lhomel C , Eisinger F 
Published: August 2014

Abstract
Background: It has been more than 20 years since local initiatives were proposed and 8 years since national organized breast cancer screening (BCS) (nationwide coverage) was implemented in France. It was associated with mass media and professional information for women with the aim of increasing the participation rate. The current reported coverage rate for women aged 50-74 every other year is about 80%. However the fairness of the process had not yet been assessed. It appears that having information about the pros and cons of BCS is thus a critical issue for targeted women.
Methodology: A nationwide observational study, recorded in the EDIFICE iterative surveys, with a representative sample of 451 women living in France aged 40-75 years old, was carried out in January 2013, using the quota method. The survey questionnaire was conducted using a computer-assisted telephone interviewing technique (CATI) 3 months after the beginning of a worldwide controversy spread by the mass media on BCS.
Results: The vast majority of women are reassured by BCS (74% vs. 13%). However 39% reported that they were stressed by BCS, with the main reason being fear of the results (30%) rather than the examination itself (9%). The main-reported benefits consisted of early detection of BC (38%), increased cure rate (22%) and preventing breast cancer (10%). The main reported limitations are a long period between two examinations (21%), starting too late (19%) and not being reliable enough (14%). A few people spontaneously reported screening-related risks (14%); the main risk being radiation-induced cancer (6%) false positives, over diagnosis and over treatment (5%). 18% have already heard about over diagnosis. With early detection of BC, 79% of women think that they will have only loco regional treatment, 3% think they will avoid major surgery, and only 10% of them think they will still have systemic treatment.
Conclusion: Overall women have a fair level of knowledge about the pros and cons of BCS. They are generally confident in BCS, but they underestimate its limitations and adverse effects, and have a lack of knowledge about the impact of BCS on therapeutic management. This appears to be a target for the next step in women: delivering honest and relevant information about BCS.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-04-05.